Waheed Asghar1, Fakhreddin Jamali. 1. Faculty of Pharmacy & Pharmaceutical Sciences, University of Alberta, 11361 - 87 Avenue, Edmonton, AB, T6G 2E1, Canada.
Abstract
PURPOSE: Non-steroidal anti-inflammatory drugs (NSAIDs) are known to increase the risk of cardiovascular (CV) and renal incidences, especially at higher doses and upon long term use. However, the available reports are criticized for lack of specificity, grouping of vastly different outcomes together and ignoring the heterogeneity among NSAIDs. In this systematic review, we are reporting CV/renal risks associated with meloxicam, stratified into myocardial, vascular, renal risk categories, to address the differential nature of NSAIDs effects on different body systems. We are also reporting composite CV/renal risk to present overall risk associated with various covariates. METHODS: We searched the online healthcare databases for observational studies or randomized controlled trials, reporting myocardial or all-cause mortality outcome (>90 days exposure) and/or vascular/renal outcomes (any exposure) after meloxicam use, published until April 2014. The combined odd ratio values (OR'; 95% CI) were calculated using the random effect inverse variance model. RESULTS: We found 19 eligible studies out of 2,422 reports. Meloxicam demonstrated a low increase in composite risk (OR' 1.14; CI 1.04-1.25) which was mainly vascular in nature (OR' 1.35; CI 1.18-1.55] as it did not elevate myocardial (OR' 1.13; CI 0.98-1.32) or renal (OR', 0.99; CI 0.72-1.35) risks. Relative to meloxicam, other NSAIDs increased the composite risk, in a dose-dependent fashion, in the following order: rofecoxib > indomethacin > diclofenac > celecoxib > naproxen > ibuprofen. OR' was also influenced by type of disease and the comparator used, and acetylsalicylic acid. CONCLUSION: NSAIDs are heterogeneous in increasing CV/renal risks. The low increased risk associated with meloxicam is mainly vascular in origin.
PURPOSE: Non-steroidal anti-inflammatory drugs (NSAIDs) are known to increase the risk of cardiovascular (CV) and renal incidences, especially at higher doses and upon long term use. However, the available reports are criticized for lack of specificity, grouping of vastly different outcomes together and ignoring the heterogeneity among NSAIDs. In this systematic review, we are reporting CV/renal risks associated with meloxicam, stratified into myocardial, vascular, renal risk categories, to address the differential nature of NSAIDs effects on different body systems. We are also reporting composite CV/renal risk to present overall risk associated with various covariates. METHODS: We searched the online healthcare databases for observational studies or randomized controlled trials, reporting myocardial or all-cause mortality outcome (>90 days exposure) and/or vascular/renal outcomes (any exposure) after meloxicam use, published until April 2014. The combined odd ratio values (OR'; 95% CI) were calculated using the random effect inverse variance model. RESULTS: We found 19 eligible studies out of 2,422 reports. Meloxicam demonstrated a low increase in composite risk (OR' 1.14; CI 1.04-1.25) which was mainly vascular in nature (OR' 1.35; CI 1.18-1.55] as it did not elevate myocardial (OR' 1.13; CI 0.98-1.32) or renal (OR', 0.99; CI 0.72-1.35) risks. Relative to meloxicam, other NSAIDs increased the composite risk, in a dose-dependent fashion, in the following order: rofecoxib > indomethacin > diclofenac > celecoxib > naproxen > ibuprofen. OR' was also influenced by type of disease and the comparator used, and acetylsalicylic acid. CONCLUSION: NSAIDs are heterogeneous in increasing CV/renal risks. The low increased risk associated with meloxicam is mainly vascular in origin.
Authors: Robert S Bresalier; Robert S Sandler; Hui Quan; James A Bolognese; Bettina Oxenius; Kevin Horgan; Christopher Lines; Robert Riddell; Dion Morton; Angel Lanas; Marvin A Konstam; John A Baron Journal: N Engl J Med Date: 2005-02-15 Impact factor: 91.245
Authors: Sara Biere-Rafi; Marcello Di Nisio; Victor Gerdes; Ettore Porreca; Patrick Souverein; Anthonius Boer; Harry Büller; Pieter Kamphuisen Journal: Pharmacoepidemiol Drug Saf Date: 2011-06 Impact factor: 2.890
Authors: F Salvo; A Fourrier-Réglat; F Bazin; P Robinson; N Riera-Guardia; M Haag; A P Caputi; N Moore; M C Sturkenboom; A Pariente Journal: Clin Pharmacol Ther Date: 2011-04-06 Impact factor: 6.875
Authors: Y-F Chen; P Jobanputra; P Barton; S Bryan; A Fry-Smith; G Harris; R S Taylor Journal: Health Technol Assess Date: 2008-04 Impact factor: 4.014
Authors: Eric Yuk Fai Wan; Esther Yee Tak Yu; Linda Chan; Anna Hoi Ying Mok; Yuan Wang; Esther Wai Yin Chan; Ian Chi Kei Wong; Cindy Lo Kuen Lam Journal: Clin J Am Soc Nephrol Date: 2021-04-28 Impact factor: 10.614
Authors: David Rodriguez Sanz; Francisco Unda Solano; Daniel López López; Irene Sanz Corbalan; Carlos Romero Morales; Cesar Calvo Lobo Journal: Arch Med Sci Date: 2017-09-26 Impact factor: 3.318